Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Sept. 12 (Korea Bizwire) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price [...]